128 related articles for article (PubMed ID: 30210638)
1. Covalent CDK7 Inhibitor THZ1 Inhibits Myogenic Differentiation.
Ma X; Kuang X; Xia Q; Huang Z; Fan Y; Ning J; Wen J; Zhang H; Yan J; Zhang Q; Shen H; Long C
J Cancer; 2018; 9(17):3149-3155. PubMed ID: 30210638
[TBL] [Abstract][Full Text] [Related]
2. CDK7 inhibitor suppresses tumor progression through blocking the cell cycle at the G2/M phase and inhibiting transcriptional activity in cervical cancer.
Zhong S; Zhang Y; Yin X; Di W
Onco Targets Ther; 2019; 12():2137-2147. PubMed ID: 30962695
[TBL] [Abstract][Full Text] [Related]
3. CDK7 Inhibitor THZ1 Induces the Cell Apoptosis of B-Cell Acute Lymphocytic Leukemia by Perturbing Cellular Metabolism.
Abudureheman T; Xia J; Li MH; Zhou H; Zheng WW; Zhou N; Shi RY; Zhu JM; Yang LT; Chen L; Zheng L; Xue K; Qing K; Duan CW
Front Oncol; 2021; 11():663360. PubMed ID: 33889549
[TBL] [Abstract][Full Text] [Related]
4. Anti-tumor Drug THZ1 Suppresses TGFβ2-mediated EMT in Lens Epithelial Cells via Notch and TGFβ/Smad Signaling Pathway.
Ning J; Ma X; Long C; Mao Y; Kuang X; Huang Z; Fan Y; Zhang H; Xia Q; Wang R; Liang Y; Lin S; Zhang Q; Shen H
J Cancer; 2019; 10(16):3778-3788. PubMed ID: 31333795
[TBL] [Abstract][Full Text] [Related]
5. THZ1, a covalent CDK7 inhibitor, enhances gemcitabine-induced cytotoxicity via suppression of Bcl-2 in urothelial carcinoma.
Kuo KL; Lin WC; Liu SH; Hsu FS; Kuo Y; Liao SM; Yang SP; Wang ZH; Hsu CH; Huang KH
Am J Cancer Res; 2021; 11(1):171-180. PubMed ID: 33520367
[TBL] [Abstract][Full Text] [Related]
6. DNA methyltransferase inhibitor CDA-II inhibits myogenic differentiation.
Chen Z; Jin G; Lin S; Lin X; Gu Y; Zhu Y; Hu C; Zhang Q; Wu L; Shen H
Biochem Biophys Res Commun; 2012 Jun; 422(3):522-6. PubMed ID: 22627135
[TBL] [Abstract][Full Text] [Related]
7. Converged DNA Damage Response Renders Human Hepatocellular Carcinoma Sensitive to CDK7 Inhibition.
Xie G; Zhu A; Gu X
Cancers (Basel); 2022 Mar; 14(7):. PubMed ID: 35406486
[TBL] [Abstract][Full Text] [Related]
8. SOX9 interacts with FOXC1 to activate MYC and regulate CDK7 inhibitor sensitivity in triple-negative breast cancer.
Tang L; Jin J; Xu K; Wang X; Tang J; Guan X
Oncogenesis; 2020 May; 9(5):47. PubMed ID: 32398735
[TBL] [Abstract][Full Text] [Related]
9. Cdk7 Is Required for Activity-Dependent Neuronal Gene Expression, Long-Lasting Synaptic Plasticity and Long-Term Memory.
He G; Yang X; Wang G; Qi J; Mao R; Wu Z; Zhou Z
Front Mol Neurosci; 2017; 10():365. PubMed ID: 29163040
[TBL] [Abstract][Full Text] [Related]
10. Role of the α2 subunit of AMP-activated protein kinase and its nuclear localization in mitochondria and energy metabolism-related gene expressions in C2C12 cells.
Okamoto S; Asgar NF; Yokota S; Saito K; Minokoshi Y
Metabolism; 2019 Jan; 90():52-68. PubMed ID: 30359677
[TBL] [Abstract][Full Text] [Related]
11. Lipopolysaccharide inhibits myogenic differentiation of C2C12 myoblasts through the Toll-like receptor 4-nuclear factor-κB signaling pathway and myoblast-derived tumor necrosis factor-α.
Ono Y; Sakamoto K
PLoS One; 2017; 12(7):e0182040. PubMed ID: 28742154
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of mechanosensitive cation channels inhibits myogenic differentiation by suppressing the expression of myogenic regulatory factors and caspase-3 activity.
Wedhas N; Klamut HJ; Dogra C; Srivastava AK; Mohan S; Kumar A
FASEB J; 2005 Dec; 19(14):1986-97. PubMed ID: 16319142
[TBL] [Abstract][Full Text] [Related]
13. Targeting transcriptional kinase of CDK7 halts proliferation of multiple myeloma cells by modulating the function of canonical NF-kB pathway and cell cycle regulatory proteins.
Dutta RP; Kumar R; Tembhare PR; Bagal B; Swain RK; Hasan SK
Transl Oncol; 2023 Sep; 35():101729. PubMed ID: 37369156
[TBL] [Abstract][Full Text] [Related]
14. Elevation of effective p53 expression sensitizes wild-type p53 breast cancer cells to CDK7 inhibitor THZ1.
Wang Y; Zhang Z; Mi X; Li M; Huang D; Song T; Qi X; Yang M
Cell Commun Signal; 2022 Sep; 20(1):96. PubMed ID: 36058938
[TBL] [Abstract][Full Text] [Related]
15. Interleukin 17 inhibits myogenic and promotes osteogenic differentiation of C2C12 myoblasts by activating ERK1,2.
Kocić J; Santibañez JF; Krstić A; Mojsilović S; Dorđević IO; Trivanović D; Ilić V; Bugarski D
Biochim Biophys Acta; 2012 Apr; 1823(4):838-49. PubMed ID: 22285818
[TBL] [Abstract][Full Text] [Related]
16. Revisiting the Function of CDK7 in Transcription by Virtue of a Recently Described TFIIH Kinase Inhibitor.
Coin F; Egly JM
Mol Cell; 2015 Aug; 59(4):513-4. PubMed ID: 26295956
[TBL] [Abstract][Full Text] [Related]
17. Cyclin-dependent kinase 7 inhibitor THZ1 in cancer therapy.
Li BB; Wang B; Zhu CM; Tang D; Pang J; Zhao J; Sun CH; Qiu MJ; Qian ZR
Chronic Dis Transl Med; 2019 Sep; 5(3):155-169. PubMed ID: 31891127
[TBL] [Abstract][Full Text] [Related]
18. CDK7 inhibition is a novel therapeutic strategy against GBM both in vitro and in vivo.
Meng W; Wang J; Wang B; Liu F; Li M; Zhao Y; Zhang C; Li Q; Chen J; Zhang L; Tang Y; Ma J
Cancer Manag Res; 2018; 10():5747-5758. PubMed ID: 30532595
[TBL] [Abstract][Full Text] [Related]
19. Bone morphogenetic protein-2 inhibits terminal differentiation of myogenic cells by suppressing the transcriptional activity of MyoD and myogenin.
Katagiri T; Akiyama S; Namiki M; Komaki M; Yamaguchi A; Rosen V; Wozney JM; Fujisawa-Sehara A; Suda T
Exp Cell Res; 1997 Feb; 230(2):342-51. PubMed ID: 9024793
[TBL] [Abstract][Full Text] [Related]
20. CCAAT/Enhancer Binding Protein β inhibits myogenic differentiation via ID3.
AlSudais H; Lala-Tabbert N; Wiper-Bergeron N
Sci Rep; 2018 Nov; 8(1):16613. PubMed ID: 30413755
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
